Echo Therapeutics to Unveil Symphony® CGM System in Webcast

         Echo Therapeutics to Unveil Symphony® CGM System in Webcast

Demonstration coincides with Symphony's upcoming CE Mark pivotal trial

PR Newswire

PHILADELPHIA, May 16, 2013

PHILADELPHIA, May 16, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® CGM System as a
non-invasive, wireless, transdermal continuous glucose monitoring system,
today announced the unveiling and demonstration of its Symphony CGM System to
be used in its regulatory trials. The demonstration will take place during a
live webcast following the annual stockholders meeting on Wednesday, May 22 at
10:30am EDT.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

A demonstration of the features and functionality of the Symphony CGM System
in the critical care setting will follow a corporate presentation from Patrick
T. Mooney, M.D., Echo's Chairman and CEO. The demonstration coincides with
the final steps in the preparation for the upcoming multi-center CE Mark
pivotal trial.

"We are very excited to illustrate the ease of using Symphony. We believe
that Symphony will be an important and differentiated candidate for
hospital-based glucose monitoring that has the potential to change the
paradigm of invasive, episodic glucose monitoring. We also believe that the
needle-free, wireless and continuous features and benefits will lead to better
long-term patient outcomes," commented Dr. Mooney. "More than ever, we are
enthusiastic about the potential of Symphony and we look forward to the
commencement of the upcoming pivotal trial."

Webcast


The webcast will start at approximately 10:30am EDT on Wednesday, May 22. The
link to the webcast will be available on the Echo Therapeutics, Inc. website
at www.echotx.com under Events in the Investors section, and will be archived
for future reference.

About Echo Therapeutics


Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless, transdermal continuous glucose monitoring system. Our target is
patients who could benefit from glucose monitoring in the hospital setting,
including critical care. Significant opportunity also exists for patients
with diabetes to use Symphony in the outpatient setting. Echo is also
developing its needle-free skin preparation component of Symphony, the
Prelude^® SkinPrep System, as a platform technology to enhance drug delivery
of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony CGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony CGM System, Echo's ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to Echo's and its
partners' ability to develop, market and sell the Symphony CGM System, the
availability of substantial additional equity or debt capital to support its
research, development and product commercialization activities, and the
success of its research, development, regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its Symphony CGM System. These and other risks and uncertainties
are identified and described in more detail in Echo's filings with the
Securities and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2012, its Quarterly
Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no
obligation to publicly update or revise any forward-looking statements.

For More Information:

Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:

- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx



SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com
 
Press spacebar to pause and continue. Press esc to stop.